Plasmapheresis for Frailty
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is designed to evaluate the efficacy of albumin-infused plasmapheresis, using the Fresenius Kabi 'Amicus' apheresis machine, among patients with age-related frailty characterized by reduced physical, cognitive and immunological functioning. Additionally, this study is designed to evaluate the safety and tolerability of repeated plasmapheresis treatment.
Who Is on the Research Team?
Sheldon Jordan, MD
Principal Investigator
Neurological Associates The Interventional Group
Are You a Good Fit for This Trial?
This trial is for people aged 50-95 showing signs of age-related frailty, which includes weakened physical, cognitive, and immune functions. Participants must score between 3 and 7 on the CSHA Clinical Frailty Scale. It's not open to pregnant or breastfeeding women, those with terminal illnesses, syphilis, inability to lay still for long periods, or with rashes/open wounds.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive plasmapheresis once a month for six months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Therapeutic Plasma Exchange (TPE)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Neurological Associates of West Los Angeles
Lead Sponsor